Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

=================

CHAMPIONS TACKLING MS - AWARDS Dinner, Honoring Aaron Boster, MD and Jon e. Glaser, DDS - now open for registration. Visit www.events.msvn.org

Wednesday, October 26, 2016

RedHill BioPharma Awaits Patent for RHB-104, Potential MS Treatment, from Japan


                                                                  
  

Click here to receive MS news via e-mail



RedHill Biopharma recently announced that it has received a Notice of Allowance from the Japan Patent Office for a new patent covering RHB-104 as a potential treatment of multiple sclerosis (MS). Once granted, the patent will be valid until 2032.
The European Patent Office also recently approved a patent application for the drug with this indication, the company said in a press release.
RHB-104 is a novel oral capsule formulation of a therapeutic combination of antibiotics that has potent intracellular, anti-mycobacterial, and anti-inflammatory properties. The capsules consist of 95 mg of clarithromycin, 45 mg of rifabutin, and 10 mg of clofazimine. RHB-104, originally developed for the treatment of Crohn’s disease and now in a clinical trials for the condition, is also being evaluated to treat relapsing-remitting multiple sclerosis (RRMS), as its anti-inflammatory and neuroprotective properties may dampen the effects of the disease.
The Phase 2a proof-of-concept CEASE-MS (NCT01717664) trial is assessing the efficacy and safety of a fixed dose combination of RHB-104 as add-on therapy to interferon beta-1a in patients with RRMS. Participants were treated with RHB-104 plus interferon beta-1a for 24 weeks, and then assessed for an additional 24 weeks in which they received only interferon beta-1a.





MS Views and News
Providing educational information, resources and services for those affected by MS

No comments: